Publications

Journal Article
Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't
Ppublish 570 citations
Electronic publication date
December 6, 2007

View on Pubmed.gov 16818686 | View on doi.org 10.1158/1078-04...

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

Search for publications in this journal Clin Cancer Res - 12(13):3908-14

Abstract

PURPOSE

Somatic mutations in the epidermal growth factor receptor (EGFR) have been detected in patients with non-small cell lung cancer (NSCLC) and are associated with sensitivity to treatment with gefitinib or erlotinib. Our study explored the relationship between the two most common types of somatic EGFR mutations, exon 19 deletions and the L858R point mutation, and outcomes of patients following treatment with gefitinib or erlotinib.

EXPERIMENTAL DESIGN

Tumor specimens obtained before treatment with gefitinib or erlotinib were analyzed for EGFR mutations. Patients with exon 19 deletion or L858R mutations were identified. The response rate, time to progression, and overall survival were determined for the two groups.

RESULTS

We identified 36 patients with NSCLC and an EGFR mutation who were treated with gefitinib or erlotinib. Patients with an exon 19 deletion had a significantly longer overall survival compared with patients with an L858R mutation (38 versus 17 months; P = 0.04). There were also trends toward higher response rate (73% versus 50%) and improved time to progression (24 versus 10 months) for the patients with an exon 19 deletion, although these were not independently significant in a multivariate analysis. A difference in response rate for patients treated with gefitinib compared with erlotinib was also noted [18 of 23 (78%) versus 3 of 9 (33%); P = 0.04]. No obvious difference in time to progression or overall survival was noted between gefitinib- and erlotinib-treated patients.

CONCLUSIONS

Patients with NSCLC and EGFR exon 19 deletions have a longer survival following treatment with gefitinib or erlotinib compared with those with the L858R mutation. Pooling of greater numbers of patients and completion of prospective trials are needed to further define the predictive and prognostic roles of different EGFR mutations with respect to treatment with gefitinib, erlotinib, and other EGFR inhibitors.

References

No references provided.

Cited by 570 citations (total)

Consensus Development Conference Journal Article Practice Guideline

[Histology-based algorithm in the molecular diagnosis of mutations of the Epidernal Growth Factor Receptor (EGFR) in non-small cell lung cancer].

Electronic publication date January 4, 2012

Search for publications in this journal Wien Klin Wochenschr

Helmut Popper [...] Ferdinand Ploner et al.

Patients with stage IIIB and IV non-small cell lung carcinoma (NSCLC) harboring an activating mutation of the Epidermal Growth Factor...

Journal Article Research Support, N.I.H., Extramural

Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers.

Electronic publication date December 16, 2009

Search for publications in this journal Cancer Res

Lynette M Sholl [...] Lucian R Chirieac et al.

In a subset of lung adenocarcinomas, the epidermal growth factor receptor (EGFR) is activated by kinase domain mutations and/or gene...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances